Study identifies new regulator of fat metabolism

User rating: 4 / 5 after 7 vote(s)

Over the past several years, animal studies have shown that high-fat, low-carbohydrate “ketogenic” diets cause demonstrable changes in metabolism and subsequent weight loss. Now, researchers at Beth Israel Deaconess Medical Center (BIDMC) have identified a key mechanism behind this turn of events. Their findings, which appear in the June 2007 issue of Cell Metabolism, demonstrate that a liver hormone known as FGF21 is required to oxidize fatty acids – and thereby burn calories.


Full story »

All News summaries from Medicine & Health news
All News summaries for June 05, 2007

5 things you didn't know about... buying medication online

52 minutes ago | User rating: not rated yet
Cynthia Reilly, director of the practice development division of the American Society of Health-Systems Pharmacists, offers advice for shopping online:

Scientists go chatting to hear kids' drug concerns

1 hour ago | User rating: not rated yet
(AP) -- It's nothing to LOL about. Students these days often have ready access to marijuana, alcohol and tobacco but they don't feel comfortable talking about the ramifications. So, some of the nation's government ...

End-of-life discussions with physicians may have benefits for patients and caregivers

1 hour ago | User rating: not rated yet
Terminally ill patients who had end-of-life discussions with physicians were not more likely to experience emotional distress, received less aggressive medical care in their final week of life and had a better quality of ...

Older renal cancer patients appear to benefit from sorafenib treatment

1 hour ago | User rating: not rated yet
Older and younger patients with renal cancer derive similar benefit from sorafenib therapy and tolerate the drug equally well, according to a study published online October 7 in the Journal of the National Cancer Institute.

Use of medication for enlarged prostate not associated with increased risk of hip fracture

1 hour ago | User rating: not rated yet
Use of a class of medications for treating an enlarged prostate, known as 5-α reductase inhibitors, are not associated with an increased hip fracture risk, according to a study in the October 8 issue of JAMA.